Hypertension represents a major common cardiovascular risk factor. Optimal control of high
blood pressure levels is recommended to reduce the global burden of hypertensive …

This review summarizes the key findings of 14 clinical trials in which Galectin-3 was
assessed as a biomarker of heart failure. In addition, most relevant information available …

Background Actions of angiotensin II may contribute to the progression of heart failure
despite treatment with currently recommended drugs. We therefore evaluated the long-term …

Background The ELITE study showed an association between the angiotensin II antagonist
losartan and an unexpected survival benefit in elderly heart-failure patients, compared with …

BACKGROUND: Atrial fibrillation (AF) in heart failure (HF) is generally considered a
negative prognostic factor. Recent studies indicate that the incidence of AF might be …

Objectives: A subgroup analysis of the Valsartan Heart Failure Trial (Val-HeFT) was
performed to evaluate the effects of the angiotensin II receptor blocker, valsartan, in the …

Aims Plasma levels of individual neurohormones (NH) have been proposed as reliable
indicators for risk stratification of patients with heart failure (HF). Mainly because of small …

Objectives: The objective of this study was to test the hypothesis that the severity of left
ventricular remodeling predicts the response to treatment and outcomes in chronic heart …

Background—Brain natriuretic peptide (BNP) and norepinephrine (NE) are strongly related
to severity of and are independent predictors of outcome in heart failure. The long-term …

Composite endpoints are commonly used as the primary measure of efficacy in heart failure
clinical trials to assess the overall treatment effect and to increase the efficiency of trials …